{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:30:37Z","timestamp":1774503037106,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Children receiving palliative care often suffer from refractory neurological symptoms. In recent years, there has been a growing interest in the use of alpha-2 agonists as a second- or third-line therapy for severe dystonia and irritability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this review was to provide an overview of the scientific literature on the use of alpha-2 agonists for the treatment of refractory neurological symptoms in pediatric palliative care, evaluating the evidence available and identifying gaps related to their reported efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A scoping review was performed according to the PRISMA extension. A systematic search was conducted in PubMed, Medline, EMBASE, Web of Science, CINAHL, and The Cochrane Library, using terms referring to alpha-2 agonists and neurological symptoms in pediatric palliative care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven articles were identified, including three case reports, two case series, one observational cohort study, and one retrospective analysis. Two drugs (dexmedetomidine, <jats:italic>n<\/jats:italic>\u2009=\u20094\/7, and clonidine, <jats:italic>n<\/jats:italic>\u2009=\u20093\/7) were investigated, encompassing a total of 44 patients aged between 7 months and 18 years. Most patients (95%) initiated treatment in an inpatient setting before transitioning to home care. All patients reported clinical improvement; however, 25% of children treated with clonidine discontinued its use due to ineffectiveness or side effects. No adverse effects were reported with dexmedetomidine use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Alpha-2 agonists are increasingly being used to manage intractable neurological symptoms in pediatric palliative care. However, evidence regarding their safety profile and effectiveness remains limited, highlighting the need for further research in this area.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1542482","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:25:41Z","timestamp":1747239941000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Alpha-2 agonists for refractory neurological symptoms in pediatric palliative care: a scoping review"],"prefix":"10.3389","volume":"13","author":[{"given":"Annalisa","family":"Salerno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Baratiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"La Piana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Bincoletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Benini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.pop.2019.05.010","article-title":"Pediatric palliative care","volume":"46","author":"Norris","year":"2019","journal-title":"Prim Care Clin Off Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.pcl.2014.04.011","article-title":"Pediatric palliative care for children with complex chronic medical conditions","volume":"61","author":"Schwantes","year":"2014","journal-title":"Pediatr Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1155\/2013\/193937","article-title":"Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment","volume":"18","author":"Siden","year":"2013","journal-title":"Pain Res Manag"},{"key":"B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/pch\/20.3.159","article-title":"Challenging neurological symptoms in paediatric palliative care: an approach to symptom evaluation and management in children with neurological impairment","volume":"20","author":"Rasmussen","year":"2015","journal-title":"Paediatr Child Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/01.mop.0000139300.13152.20","article-title":"Pharmacologic management of behavioral instability in medically ill pediatric patients","volume":"16","author":"Cummings","year":"2004","journal-title":"Curr Opin Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.pcl.2007.06.004","article-title":"Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity","volume":"54","author":"Wusthoff","year":"2007","journal-title":"Pediatr Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/apa.16663","article-title":"International project on troublesome symptoms in paediatric palliative care will focus on neuro-irritability, dystonia and sleep disorders","volume":"112","author":"Avagnina","year":"2023","journal-title":"Acta Paediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ejpn.2017.03.001","article-title":"Clonidine use in the outpatient management of severe secondary dystonia","volume":"21","author":"Sayer","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/bcpt.13979","article-title":"Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care","volume":"134","author":"Amna","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/bmjspcare-2015-001010","article-title":"Changing from continuous SC to transdermal clonidine to treat dystonia in a teenage boy with end-stage leucodystrophy","volume":"8","author":"McCluggage","year":"2018","journal-title":"BMJ Support Palliat Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40262-017-0507-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine","volume":"56","author":"Weerink","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/0269216314556923","article-title":"A case report of dexmedetomidine used to treat intractable pain and delirium in a tertiary palliative care unit","volume":"29","author":"Hilliard","year":"2015","journal-title":"Palliat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0292016","DOI":"10.1371\/journal.pone.0292016","article-title":"Dexmedetomidine use for patients in palliative care with intractable pain and delirium: a retrospective study","volume":"18","author":"Yu","year":"2023","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/15360288.2022.2102705","article-title":"Dexmedetomidine continuous infusion for refractory cancer pain at end of life: a case report","volume":"36","author":"Byrne","year":"2022","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e820","DOI":"10.1136\/spcare-2022-003651","article-title":"Efficacy and safety of subcutaneous clonidine for refractory symptoms in palliative medicine: a retrospective study","volume":"13","author":"Howard","year":"2023","journal-title":"BMJ Support Palliat Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.11124\/JBIES-21-00483","article-title":"What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis","volume":"20","author":"Munn","year":"2022","journal-title":"JBI Evid Synth"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.jpainsymman.2021.12.031","article-title":"International standards for pediatric palliative care: from IMPaCCT to GO-PPaCS","volume":"63","author":"Benini","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1089\/jpm.2022.0420","article-title":"Novel use of intranasal dexmedetomidine for refractory irritability in pediatric home care","volume":"26","author":"Bartoletta","year":"2023","journal-title":"J Palliat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1089\/jpm.2016.0419","article-title":"The use of dexmedetomidine in pediatric palliative care: a preliminary study","volume":"20","author":"Burns","year":"2017","journal-title":"J Palliat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jpainsymman.2020.02.022","article-title":"Home intranasal dexmedetomidine for refractory dystonia in pediatric palliative care","volume":"59","author":"De Zen","year":"2020","journal-title":"J Pain Symptom Manage"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/j.jpainsymman.2023.07.018","article-title":"Dexmedetomidine at home for intractable dystonia and insomnia in children with special needs: a case series","volume":"66","author":"De Zen","year":"2023","journal-title":"J Pain Symptom Manage"},{"key":"B25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ejpn.2017.07.007","article-title":"Safety and efficacy of high-dose enteral, intravenous, and transdermal clonidine for the acute management of severe intractable childhood dystonia and status dystonicus: an illustrative case-series","volume":"21","author":"Nakou","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jpainsymman.2021.07.026","article-title":"The parental experience of caring for a child with pain and irritability of unknown origin","volume":"63","author":"Rizakos","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-59745-476-6","volume-title":"Pain in Children","author":"Walco","year":"2008"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1542\/peds.2006-1609","article-title":"Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment","volume":"119","author":"Hauer","year":"2007","journal-title":"Pediatrics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1592\/phco.29.8.997","article-title":"Gabapentin therapy for pain and irritability in a neurologically impaired infant","volume":"29","author":"Haney","year":"2009","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0285584","DOI":"10.1371\/journal.pone.0285584","article-title":"Long-term consequences of benzodiazepine-induced neurological dysfunction: a survey","volume":"18","author":"Ritvo","year":"2023","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5863\/1551-6776-29.2.159","article-title":"Evaluating gabapentin dosing, efficacy and safety in infants","volume":"29","author":"Fleser","year":"2024","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/MOP.0000000000000555","article-title":"Advances in pharmacotherapies for movement disorders in children: current limitations and future progress","volume":"29","author":"Lin","year":"2017","journal-title":"Curr Opin Pediatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/children11070821","article-title":"Polypharmacy in children with medical complexity: a cross-sectional study in a pediatric palliative care center","volume":"11","author":"Zanin","year":"2024","journal-title":"Children"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2024-004282","article-title":"Taking care of caregivers: enhancing proper medication management for palliative care children with polypharmacy","author":"Mengato","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"B35","doi-asserted-by":"publisher","first-page":"738","DOI":"10.30773\/pi.2022.0117","article-title":"Effectiveness of clonidine in child and adolescent sleep disorders","volume":"19","author":"Jang","year":"2022","journal-title":"Psychiatry Investig"},{"key":"B36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fneur.2017.00032","article-title":"The efficacy and tolerability of the clonidine transdermal patch in the treatment for children with Tic disorders: a prospective, open, single-group, self-controlled study","volume":"8","author":"Song","year":"2017","journal-title":"Front Neurol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders","volume":"30","author":"Ming","year":"2008","journal-title":"Brain Dev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/0009922813502123","article-title":"A review of the use of clonidine as a sleep aid in the child and adolescent population","volume":"53","author":"Nguyen","year":"2014","journal-title":"Clin Pediatr (Phila)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res Bull"},{"key":"B40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e40933","DOI":"10.15253\/2175-6783.20192040933","article-title":"Complica\u00e7\u00f5es da via subcut\u00e2nea na infus\u00e3o de medicamentos e solu\u00e7\u00f5es em cuidados paliativos","volume":"20","author":"Guedes","year":"2019","journal-title":"Rev Rene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/j.jpainsymman.2023.05.011","article-title":"Pediatric palliative care at home: a prospective study on subcutaneous drug administration","volume":"66","author":"Garc\u00eda-L\u00f3pez","year":"2023","journal-title":"J Pain Symptom Manage"},{"key":"B43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/NAN.0b013e31824237ce","article-title":"Intravenous therapy: a review of complications and economic considerations of peripheral access","volume":"35","author":"Dychter","year":"2012","journal-title":"J Infus Nurs"},{"key":"B44","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1542482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:25:42Z","timestamp":1747239942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1542482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":44,"alternative-id":["10.3389\/fped.2025.1542482"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1542482","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1542482"}}